



Mendeleev Communications

Synthesis of diethyl (aryl)(4-oxopiperidin-1-yl)methylphosphonates

Mikhail V. Makarov,* Evgenii A. Skvortsov and Valery K. Brel

A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 119991 Moscow, Russian Federation. Fax: +7 499 135 5085; e-mail: mmak78@yandex.ru


DOI: 10.1016/j.mencom.2015.05.026

The Kabachnik–Fields reaction of 4-piperidone hydrochloride monohydrate, an aromatic aldehyde and triethyl phosphite in the presence of triethylamine and magnesium perchlorate affords diethyl (aryl)(4-oxopiperidin-1-yl)methylphosphonates in moderate yields.

 γ -Piperidones, especially their N-derivatives, reveal versatile biological activities¹ including neurotropic² and anticancer properties.³ On the other hand, phosphorus-containing modifiers are of special importance as they improve solubility and bioavailability of biologically active compounds and drugs and facilitate the delivery of a pharmacophore to a biological target.⁴ In this regard, attaching phosphonate group to piperidone framework will result in piperidone-containing amino phosphonates that may be considered as phosphorus analogues of amino acid esters and, therefore, become prospective drug candidates.⁵ Previously, we prepared diethyl β -aminoethyl-, γ -aminopropyl- and δ -aminobutylphosphonates bearing 4-piperidone fragment.⁶ The aim of the present work was to obtain their lower homologue of α -aminomethylphosphonate type.

The Kabachnik–Fields reaction⁷ between aldehydes, amines and dialkyl phosphites is the most general, convenient and straightforward way to dialkyl α -aminomethylphosphonates.^{8,9} In another version, trialkyl phosphites can be used as phosphorus components instead of dialkyl phosphites.^{10,11}

Herein, we describe the straightforward synthesis of novel diethyl (aryl)(4-oxopiperidin-1-yl)methylphosphonates **2a–f** from commercially available 4-piperidone hydrochloride monohydrate **1**, an aromatic aldehyde and (EtO)₃P in the presence of catalytic amounts of anhydrous Mg(ClO₄)₂ (Scheme 1).[†] Triethylamine was used as a base in equimolar amount to amine hydrochloride **1**.



Scheme 1

Application of catalytic amounts (5 mol%) of convenient anhydrous $Mg(ClO_4)_2$ for similar purpose was described previously, both $(EtO)_2P(O)H$ and $(EtO)_3P$ having been equally

Diethyl (4-oxopiperidin-1-yl)(phenyl)methylphosphonate **2b**: viscous liquid, yield 32%. ¹H NMR (400 MHz, CDCl₃) δ : 1.02 and 1.34 (2t, 3 H, POCH₂Me, ³J_{HH} 7.0 Hz), 2.37–2.47 [m, 4H, N(CH₂)₂], 2.73–2.79 (m, 2H), 3.12–3.18 (m, 2H), 3.63–3.73 (m, 1H, 0.5 POCH₂), 3.86–3.96 (m, 1H, 0.5 POCH₂), 4.01 (d, 1H, PCH, ²J_{PH} 22.6 Hz), 4.17–4.28 (m, 2H, POCH₂), 7.25–7.32 (m, 3H, Ph), 7.43–7.45 (m, 2H, Ph). ¹³C NMR (75 MHz, CDCl₃) δ : 16.13 and 16.58 (2d, POCH₂Me, ³J_{PC} 5.4 Hz), 41.67 (NCH₂CH₂), 51.05 (d, NCH₂CH₂, ³J_{PC} 8.8 Hz), 62.35 and 62.90 (2d, POCH₂, ²J_{PC} 7.0 Hz), 67.03 (d, PCH, ¹J_{PC} 161 Hz), 128.28 (overlapped C_{Ph}H and C_{Ph}CHP), 130.17 (d, PCH–C_{Ph}–C_{Ph}H, ³J_{PC} 8.6 Hz), 132.17 (C_{Ph}H), 208.35 (C=O). ³¹P NMR (162 MHz, CDCl₃) δ : 21.74. Found (%): C, 58.78; H, 7.09; N, 4.06; P, 9.52. Calc. for C₁₆H₂₄NO₄P (%): C, 59.07; H, 7.44; N, 4.31; P, 9.52.

Diethyl (4-methoxyphenyl)(4-oxopiperidin-1-yl)methylphosphonate **2c**: white solid mp 79.5–81.5 °C, yield 32%. ¹H NMR (400 MHz, CDCl₃) δ: 1.04 and 1.34 (2t, 3H, POCH₂Me, ³J_{HH} 7.0 Hz), 2.34–2.44 [m, 4H, N(CH₂)₂], 2.69–2.75 (m, 2H), 3.11–3.17 (m, 2H), 3.65–3.74 (m, 1H, 0.5POCH₂), 3.78 (s, 3H, OMe), 3.87–3.94 (m, 1H, 0.5POCH₂), 3.97 (d, 1H, PCH, ²J_{PH} 22.6 Hz), 4.17–4.29 (m, 2H, POCH₂), 6.85 (d, 2H, C₆H₄, ³J_{HH} 8.4 Hz), 7.37 (d, 2H, C₆H₄, ³J_{HH} 8.4 Hz). ¹³C NMR (75 MHz, CDCl₃) δ: 15.96 and 16.35 (2d, POCH₂Me, ³J_{PC} 5.4 Hz), 41.43 (NCH₂CH₂), 50.71 (d, NCH₂CH₂, ³J_{PC} 8.7 Hz), 54.92 (OMe), 62.08 and 62.64 (2d, POCH₂, ²J_{PC} 6.9 Hz), 66.00 (d, PCH, ¹J_{PC} 162 Hz), 113.36 (C_{Ph}H), 123.71 (C_{Ph}CHP), 131.17 (d, PCH–C_{Ph}-C_{Ph}H, ³J_{PC} 8.8 Hz), 159.24 (C_{Ph}–OMe), 208.21 (C=O). ³¹P NMR (162 MHz, CDCl₃) δ: 21.96. Found (%): C, 57.14; H, 7.48; N, 3.87; P, 8.89. Calc. for C₁₇H₂₆NO₅P (%): C, 57.46; H, 7.37; N, 3.94; P, 8.72.

[†] *Compounds* **2a–f** (general procedure). A mixture of 4-piperidone hydrochloride **1** (0.77 g, 5 mmol), aromatic aldehyde (5 mmol), Et₃N (0.5 g, 5 mmol), anhydrous Mg(ClO₄)₂ (0.28 g, 1.25 mmol, 25 mol%), and (EtO)₃P (0.83 g, 5 mmol) was stirred for 20 h at room temperature. Water and CH₂Cl₂ were added to the mixture, the organic phase was separated, the aqueous phase was extracted with CH₂Cl₂. The combined organic phase was washed with aqueous Na₂CO₃ solution, separated, dried over Na₂SO₄, filtered and evaporated on a rotary evaporator to give crude product as an oil. Column chromatography (30×2 cm) using gradient elution starting with light petroleum and continuing with light petroleum– acetone mixtures (gradient from 10:1 to 10:2.5) afforded the desired compounds as viscous oils. Oily products gradually transformed in white solids in the case of compounds **2a,c,e**.

 $^{^{31}}P$ NMR (162 MHz, CDCl₃) $\delta:$ 21.41. Found (%): C, 55.85; H, 6.77; N, 3.94; P, 8.90. Calc. for C₁₆H₂₃FNO₄P (%): C, 55.97; H, 6.75; N, 4.08; P, 9.02.

effective as phosphorus components.¹² Taking into consideration that hydrogen chloride and water contained in the starting amine salt **1** may bring some complications, we initially studied the outcome of a model reaction between $(EtO)_2P(O)H$ and $(EtO)_3P$, amine **1** and 4-fluorobenzaldehyde (which allows one to perform ¹⁹F NMR monitoring of the reaction).

No reaction occurred when equimolar amounts of 4-piperidone hydrochloride monohydrate, diethyl phosphite and 4-fluorobenzaldehyde were treated with 5 mol% of $Mg(ClO_4)_2$: within 6 h, the mixture contained only starting diethyl phosphite ($\delta_{\rm P}$ 7.3 ppm) and 4-fluorobenzaldehyde ($\delta_{\rm F}$ –103.5 ppm). However, on moving to triethyl phosphite, a mixture of α -(4-fluorophenyl)- α -hydroxymethylphosphonate **3a** (51 mol%) (δ_P 20.7 ppm, δ_F –114.7 ppm) and the desired amino phosphonate **2a** (22 mol%) ($\delta_{\rm P}$ 21.3 ppm, $\delta_{\rm F}$ –114.1 ppm) was obtained. Generally, in the ³¹P NMR spectra chemical shifts of a-amino(aryl)methylphosphonates were located approximately 0.3–0.5 ppm downfield of those of α -hydroxy-(aryl)methylphosphonates. The reaction mixture also contained (EtO)₃P (2.5 mol%), (EtO)₂P(O)H (4.3 mol%), and product resulting from oxidation and hydrolysis of triethyl phosphite (8.5 mol%) ($\delta_{\rm P}$ –1.54 ppm). Other by-products had phosphonate nature (δ_P in the range 33.3–22.4 ppm) and were present in small amounts (11.7 mol% in total).

When triethylamine was introduced to liberate free base from salt 1 (with molar ratio $1: Et_3N$ being 1:1), different results were obtained for diethyl and triethyl phosphites. In the case of diethyl phosphite with equimolar amounts of compound 1, 4-fluorobenzaldehyde, Et₃N and 5 mol% of Mg(ClO₄)₂, the Abramov reaction proceeded giving exclusively hydroxymethylphosphonate 3a (δ_P 21.12 ppm, doublet with ${}^6J_{PF}$ 4.4 Hz; δ_F –115.4 ppm, doublet with ${}^{6}J_{\rm FP}$ = 4.8 Hz). The similar reaction with triethyl phosphite occurred more slowly than the above considered reactions, and after 6 h the mixture consisted of (EtO)₃P (27 mol%), (EtO)₂P(O)H (1.5 mol%), α -amino phosphonate **2a** (47 mol%), and corresponding hydroxy phosphonate 3a (15 mol%). The increase in reaction time from 6 to 24 h caused a decrease in residual amount of triethyl phosphite down to ~5 mol% with a slight increase in amounts of phosphonate 2a and α -hydroxymethylphosphonate and strong increase in amounts of above mentioned by-products of phosphonate nature.

Thus, triethylamine was found to be an essential component for the successful outcome of the synthesis of amino phosphonates **2**. When Et_3N was replaced by K_2CO_3 as a base, only hydroxy phosphonates **3** were formed. Raising the amounts of $P(OEt)_3$ resulted in growth of the fraction of above by-products containing $C-P(O)(OEt)_2$ bond.

The optimum conditions in terms of satisfactory yields of compounds 2a-f involve using 25 mol% of Mg(ClO₄)₂. Further

For characteristics of compounds 2e,f, see Online Supplementary Materials.

raising its amounts caused dropping the yields of the products. The use of acetonitrile as a solvent in the case of solid aldehydes (2,3-dimethoxy- or 2,3,4-trimethoxybenzaldehyde) to ensure better contact of reagents led to noticeable decrease in the yield. Finally, in contrast to the above cited work¹² where reactions with morpholine or piperidine were completed in 10–20 min, significantly longer reaction times were required in the case of compound 1 to consume entirely starting triethyl phosphite. Typically, after 20 h of reaction, remaining amounts of P(OEt)₃ did not exceed 5%, being even lower in many cases.

According to the ³¹P NMR data, the crude mixtures contained approximately 42–60% of compounds **2a–f**, 15–21% of the above mentioned admixtures with phosphonate structure, 15–20% of hydroxy phosphonates **3**, and 7–15% of a compound that was a product of oxidation and/or hydrolysis of P(OEt)₃. Final column chromatography afforded the desired α -amino phosphonates **2a–f** in moderate yields (32–51%).

In conclusion, this study has demonstrated that(aryl)(4-oxopiperidin-1-yl)methylphosphonates can be obtained in moderate yields through the Kabachnik–Fields reaction between 4-piperidone hydrochloride monohydrate, an aromatic aldehyde and triethyl phosphite in the presence of triethylamine and magnesium perchlorate as a catalyst.

This work was supported by the Russian Foundation for Basic Research (project no. 14-03-00687).

Online Supplementary Materials

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.mencom.2015.05.026.

References

- S. K. Sahu, B. K. Dubey, A. C. Tripathi, M. Koshy and S. K. Saraf, *Mini-Rev. Med. Chem.*, 2013, 13, 565.
- 2 N. M. Kurbat, K. D. Praliev, T. A. Salita, V. K. Yu and E. L. Verina, *Pharm. Chem. J.*, 1991, **25**, 450 (*Khim.-Farm. Zh.*, 1991, **25**, 20).
- 3 U. Das, R. K. Sharma and J. R. Dimmock, *Curr. Med. Chem.*, 2009, 16, 2001.
- 4 (a) J. P. Krise and V. J. Stella, Adv. Drug Delivery Rev., 1996, 19, 287;
 (b) S. J. Hecker and M. D. Erion, J. Med. Chem., 2008, 51, 2328;
 (c) K. M. Huttunen and J. Rautio, Curr. Top. Med. Chem., 2011, 11, 2265.
- 5 (a) E. K. Baylis, C. D. Campbell and J. G. Dingwall, J. Chem. Soc., Perkin Trans. 1, 1984, 2845; (b) P. Kafarski and B. Lejczak, Phosphorus Sulfur Silicon Relat. Elem., 1991, 63, 193; (c) A. Mucha, P. Kafarski and Ł. Berlicki, J. Med. Chem., 2011, 54, 5955.
- 6 M. V. Makarov, E. Yu. Rybalkina, G.-V. Röschenthaler, K. W. Short, T. V. Timofeeva and I. L. Odinets, *Eur. J. Med. Chem.*, 2009, 44, 2135.
- 7 (a) M. I. Kabachnik and T. Ya. Medved, *Dokl. Akad. Nauk SSSR*, 1952,
 83, 689 (*Chem. Abstr.*, 1953, 47, 2724b); (b) E. K. Fields, *J. Am. Chem. Soc.*, 1952, 74, 1528.
- 8 (a) R. A. Cherkasov and V. I. Galkin, *Russ. Chem. Rev.*, 1998, **67**, 857 (*Usp. Khim.*, 1998, **67**, 940); (b) G. Keglevich and E. Bálint, *Molecules*, 2012, **17**, 12821.
- 9 G. Keglevich and A. Szekrényi, Lett. Org. Chem., 2008, 5, 616.
- 10 G. Keglevich, E. Bálint, R. Kangyal, M. Bálint and M. Milen, *Heteroatom. Chem.*, 2014, 25, 282.
- 11 (a) S. M. Vahdat, R. Baharfar, M. Tajbakhsh, A. Heydari, S. M. Baghbanian and S. Khaksar, *Tetrahedron Lett.*, 2008, **49**, 6501; (b) M. Tajbakhsh, A. Heydari, H. Alinezhad, M. Ghanei and S. Khaksar, *Synthesis*, 2008, 352; (c) M. T. Maghsoodlou, S. M. Habibi-Khorassani, R. Heydari, N. Hazeri, S. S. Sajadikhah and M. Rostamizadeh, *Arab. J. Chem.*, 2011, **4**, 481.
- 12 S. Bhagat and A. K. Chakraborti, J. Org. Chem., 2007, 72, 1263.

Received: 4th August 2014; Com. 14/4438

Diethyl (4-oxopiperidin-1-yl)(2-thienyl)methylphosphonate **2d**: yellowish viscous liquid, yield 35%. ¹H NMR (400 MHz, CDCl₃) δ: 1.14 and 1.37 (2t, 3 H, POCH₂Me, ³J_{HH} 7.0 Hz), 2.46 [t, 4 H, N(CH₂)₂, ³J_{HH} 5.9 Hz], 2.78–2.85 (m, 2H), 3.19–3.26 (m, 2H, CH₂), 3.85–3.95 (m, 1H, 0.5 POCH₂), 4.21–4.30 (m, 2 H, POCH₂), 4.35 (d, 1H, PCH, ²J_{PH} 24.4 Hz), 7.02 (dd, 1H, ³J_{HH} 3.6 Hz, ³J_{HH} 5.0 Hz), 7.24 (m, 1H), 7.8 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 16.08 and 16.46 (2d, POCH₂Me, ³J_{PC} 5.6 Hz), 41.61 (NCH₂CH₂), 50.50 (d, NCH₂CH₂, ³J_{PC} 8.0 Hz), 61.36 (d, PCH, ¹J_{PC} 164 Hz), 62.39 and 63.16 (2d, POCH₂, ²J_{PC} 7.1 Hz), 125.73 (d, ⁴J_{PC} 1.5 Hz), 126.88, 128.44 (d, ³J_{PC} 6.3 Hz), 133.38 (d, ²J_{PC} 7.3 Hz), 208.06 (C=O). ³¹P NMR (162 MHz, CDCl₃) δ: 20.57. Found (%): C, 50.54; H, 7.01; N, 4.25. Calc. for C₁₄H₂₂NO₄PS (%): C, 50.75; H, 6.69; N, 4.23.